

eASOAP FORM


ADMINISTRATIVE
The member is allowed for **Out Patient**at the **CITICARE MEDICAL CENTER LLC**

Patent Name:	Heba Momtaz	Gender:	Female	Validity Between:	01/01/2024 and 31/12/2026
Card No:	FDCB-4BC9-73C3-A85B	DOB:	9/24/1979 12:00:00 AM	Coverage Informaton for:	Out Patient
Pin #:		Identty Card:		Network:	RN UAE (Al Ansari-AUH)-MEDGULF
Natonal ID:	784-1979-5396036-2	Service Date:	29-Oct-2024	Radiology:	Covered
		Patent's Tel No:	0562600065		
Policy Holder:		Threshold Limit:			
Payer Name:	DUBAI GOVERNMENT - PROGRAM 1 (ENAYA)	Class:	Normal		
		Out-Patent :			
Category:	Category B	Patent's File No:	42850	Pharmacy:	Co-Part: 20%
Gatekeeper:	No	Consultaton :		Laboratory:	Covered
Referral No:					
Referred Service:					

SUBJECTIVE ASSESSMENT

Symptom(s) as described by the patent (Chief Complaint):				Date of Symptoms/illness started		
Complaint				DD	MM	YYYY
PC: Cough, chest pain, weakness, headache and dry mouth. There is no fever. Duration: 3days (23/10/2024) Known diabetic, hyperlipidemic patient and hypertensive. Known asthmatic also. Last acute attack in April (6months ago). Claims last HbA1c 3days ago) was good and random blood sugar is normal (139mg/dl). Lipid is however derranged. Patient is counselled on the need for weight reduction and diet modification. For CBC, FBS, HbA1c, lipid panel and urinalysis.						
Past Medical Surgical History? ☐ Yes ☐ No				Date of Symptoms/illness started DD MM YYYY		
Obs/Gyn Claims				Date of Symptoms/illness started DD MM YYYY		
☐ Para	☐ Gravida:	☐ AB:	LMP:	Marital Status:	Marital Date:	
What date did the Patient first feel same / similar Symptom(s) : dd mm yyyy						
Is the Patient under any type of Treatment? ☐ Yes ☐ No if yes, indicate what Assessment and since when:						

OBJECTIVE / ASSESSMENT(To be completed by Physician)

Clinical Findings :	Vital Signs : B/P : 152 : 18	T : 36.6	HR : 100	RR
----------------------------	---------------------------------	----------	----------	----

Assessment/Diagnosis : ☐ Acute ☐ Chronic ☐ Confirmed ☐ Suspected
INDICATE DIAGNOSIS NOT SYMPTOM

Type	Code	Diagnosis
Primary	J20.9	Acute bronchitis, unspecified
Secondary	J45.20	Mild intermittent asthma, uncomplicated
Secondary	I10	Essential (primary) hypertension
Secondary	E11.9	Type 2 diabetes mellitus without complications
Secondary	K21.9	Gastro-esophageal reflux disease without esophagitis
Secondary	E78.5	Hyperlipidemia, unspecified

ACCIDENT/OCCUPATIONAL Claim Informaton (complete if claim is a result of accident or work related illness/injury)

Accident or illness due to work?	Injury due to road accident?	Describe how the accident or work related injury/illness occur:
☐ Yes ☐ No	☐ Yes ☐ No	
Date of accident or beginning of illness:		


MEDICAL PLAN Itemized Original Invoices and Applicable Prescriptions / Reports / Results must be enclosed to consider claim

CPT Code	Treatment	Type	Price
9	GP Consultation	General Consultation	25.0000
81001	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy	Lab	8.0000
83036	Hemoglobin; glycosylated (A1C)	Lab	30.0000
82947	Glucose; quantitative, blood (except reagent strip)	Lab	12.0000
80061	Lipid panel This panel must include the following: Cholesterol, serum, total (82465), Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718), Triglycerides (84478)	Lab	45.0000
86140	C-reactive protein;	Lab	15.0000
85025	Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	Lab	20.0000

Code	Generic	Duration	Instructions
0281-367801-0431	(CALCIPOTRIOL : 50 MCG/G) (BETAMETHASONE (AS DIPROPIONATE) : 0.5 MG/G) GEL	30	Take 1Cream 3Time(s) perDay For 30 Day(s) others
0188-155601-0391	(ROSUVASTATIN (AS CALCIUM) : 20 MG) FILM COATED TABLETS	56	Take 1Tablets 1 Time(s) per Day For 56 Day(s) evening
0188-135906-2441	(BUDESONIDE : 0.5 MG/ML) SUSPENSION FOR NEBULIZATION	30	Take 1Units 1Time(s) perDay For 30 Day(s) evening
1614-530501-0611	(DEXLANSOPRAZOLE : 60 MG) MODIFIED RELEASE CAPSULES	28	Take 1Tablets 1 Time(s) per Day For 28 Day(s) before meal
0027-179203-0391	(AMLODIPINE : 5 MG) (VALSARTAN : 160 MG) FILM COATED TABLETS	56	Take 1Tablets 1Time(s) perDay For 56 Day(s) morning
0090-265901-1171	(MONTELUKAST : 10 MG) TABLETS	28	Take 1Tablets 1 Time(s) per Day For 28 Day(s) evening
0188-272103-0791	(BUDESONIDE : 160 MCG) (FORMOTEROL FUMARATE : 4.5 MCG) POWDER FOR INHALATION	60	Take 2Puff 1 Time(s) per Day For 60 Day(s) evening

☐ Pharmacy:	Estimated Costs	☐ Laboratory / Radiology:	Estimated Costs
Is the following required	☐ Surgery:	☐ Endoscopy:	
	☐ Physiotherapy:	☐ Other Procedures:	

	If yes please specify
--	-----------------------

Is In-patient Required ? Length of Stay	Indicate Provider	Estimate Cost
<i>I hereby certify that all informaton mentoned are correct & that the medical services shown on this form were medically indicated & necessary for the management of this case.</i>		
<i>I hereby authorize any Healthcare Provider, Insurer, Employer or other Organizaton to release any informaton regarding my medical conditon and history to NEXtCARE for the purpose of determining insurance benefets. Medical management is the sole responsibility of doctor and the patent.</i>		
Treating Physician Name : Enomen Goodluck		
Tel / Fax (important):		
<i>Signature & Stamp</i>  Dr. Enomen Goodluck Ekata General Practitioner DHA No: 28040827-001 CITICARE MEDICAL CENTER LLC DUBAI - U.A.E. <i>Patient's Signature(Parent if minor)</i>		
Date :		
Date : 29-Oct-2024		
Note: Claims must be submitted along with supportng documents within 30 days from date of service		

Disclaimer: NEXtCARE ASOAP form is used for claim creaton purposes. The data contained here should always be carefully reviewed. NEXtCARE will not be held responsible for misuse of claims submission's or any adverse effects caused due to the claims submissions. NEXtCare assumes no responsibility for any discrepancies or errors contained in this pre-printed datasheet and fnal opinion will be given by the NEXtCARE claims doctors.